Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1

Conditions

Myelodysplastic Syndromes 87Leukemia, Myelogenous, Chronic, BCR-ABL Positive 71Leukemia, Myeloid, Acute 66Leukemia 64Myeloproliferative Disorders 60Precursor Cell Lymphoblastic Leukemia-Lymphoma 45Primary Myelofibrosis 39Leukemia, Myeloid, Chronic-Phase 39Leukemia, Myelomonocytic, Chronic 38Polycythemia Vera 32Lymphoma, Non-Hodgkin 29Lymphoma 29Multiple Myeloma 28Leukemia, Lymphocytic, Chronic, B-Cell 28Hodgkin Disease 27Lymphoma, Large B-Cell, Diffuse 26Lymphoma, Mantle-Cell 25Burkitt Lymphoma 25Leukemia, Myeloid, Accelerated Phase 24Lymphoma, Large-Cell, Immunoblastic 23Lymphoma, Follicular 23Lymphoma, B-Cell, Marginal Zone 23Blast Crisis 23Thrombocythemia, Essential 20Lymphoma, T-Cell, Cutaneous 19Leukemia, Hairy Cell 18Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 17Anemia, Refractory, with Excess of Blasts 17Neoplasms, Plasma Cell 16Myelodysplastic-Myeloproliferative Diseases 16

Interventions

bosutinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Pathologic Processes × Myeloid × Clear all
NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Pfizer

Phase 3 Completed
536 enrolled 24 charts 1 FDA
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Pathologic Processes, Philadelphia Chromosome, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡